Caza T, et al.. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int [published online ahead of print August 20, 2020]. doi: 10.1016/j.kint.2020.07.039
Sethi S, et al.. Exostosin 1/exostosin 2-associated membranous nephropathy. J Am Soc Nephrol 2019; 30:1123–1136. doi: 10.1681/ASN.2018080852
Fervenza FC, et al.. MENTOR Investigators. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381:36–46. doi: 10.1056/NEJMoa1814427
Fernández-Juárez G, et al.. STARMEN Investigators. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int [published online ahead of print November 7, 2020]. doi: 10.1016/j.kint.2020.10.014
Delbarba E, et al.. Rituximab vs. cyclosphosphamide in the treatment of membranous nephropathy: The RI-CYCLO trial. Presented as Poster PO2638 at Kidney Week Reimagined virtual conference, October 19–25, 2020.
Furie R, et al.. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020; 383:1117–1128. doi: 10.1056/NEJMoa2001180
Dooley MA, et al.. ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365:1886–1895. doi: 10.1056/NEJMoa1014460
Rovin BH, et al.. Management of lupus nephritis (LN) with voclosporin: An update from a pooled analysis of 534 patients. Presented as Poster PO1917 at Kidney Week Reimagined virtual conference, October 19–25, 2020.
Rauen T, et al.. STOP-IgAN Investigators. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:2225–2236. doi: 10.1056/NEJMoa1415463
Lv J, et al.. TESTING Study Group. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 2017; 318:432–442. doi: 10.1001/jama.2017.9362
Heerspink HJL, et al.. DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436–1446. doi: 10.1056/NEJMoa2024816
Walsh M, et al.. PEXIVAS Investigators. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 2020; 382:622–631. doi: 10.1056/NEJMoa1803537
Merkel PA, et al.. OP0011 A randomized, double-blind, active-controlled study of avacopan in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Ann Rheum Dis 2020; 79:8. doi: 10.1136/annrheumdis-2020-eular.1073